, Volume 79, Issue 18, pp 2001–2007 | Cite as

Elexacaftor/Ivacaftor/Tezacaftor: First Approval

  • Sheridan M. HoyEmail author
AdisInsight Report


A fixed-dose combination tablet of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector tezacaftor and the CFTR potentiator ivacaftor with the next-generation CFTR corrector elexacaftor (hereafter referred to as elexacaftor/ivacaftor/tezacaftor) [Trikafta™] has been developed by Vertex Pharmaceuticals Inc. to treat patients with the most common cystic fibrosis mutation (F508del). Its use has been associated with statistically significant and/or clinically meaningful improvements in lung function and respiratory-related quality of life compared with comparator regimens (placebo or ivacaftor/tezacaftor) in multinational phase II and III studies, and in October 2019 elexacaftor/ivacaftor/tezacaftor was approved by the US FDA for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene. A regulatory assessment for elexacaftor/ivacaftor/tezacaftor as a treatment for cystic fibrosis is underway in the EU. This article summarizes the milestones in the development of elexacaftor/ivacaftor/tezacaftor leading to this first approval for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Gentzsch M, Mall MA. Ion channel modulators in cystic fibrosis. Chest. 2018;154(2):383–93.CrossRefGoogle Scholar
  2. 2.
    US FDA. FDA approves new breakthrough therapy for cystic fibrosis. 2019. Accessed 23 Oct 2019.
  3. 3.
    Ren CL, Morgan RL, Oermann C, et al. Cystic Fibrosis Foundation pulmonary guidelines: use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis. Ann Am Thorac Soc. 2018;15(3):271–80.CrossRefGoogle Scholar
  4. 4.
    Rowe SM, Taylor-Cousar JL. Advancing CFTR modulator therapy for the vast majority of patients with cystic fibrosis [abstract no. S15.2]. Pediatr Pulmonol. 2019;54(Suppl 2):108–9.Google Scholar
  5. 5.
    Middleon PG, Mall MA, Dřevínek LC, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809–19.CrossRefGoogle Scholar
  6. 6.
    Vertex Pharmaceuticals Inc. Trikafta™ (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets): US prescribing information. 2019. Accessed 23 Oct 2019.
  7. 7.
    Vertex Pharmaceuticals Inc. Vertex announces European Medicines Agency Marketing Authorization Application validation for VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination treatment in cystic fibrosis. 2019. Accessed 4 Nov 2019.
  8. 8.
    Vertex Pharmaceuticals Inc. Orkambi® (lumacaftor/ivacaftor) tablets, for oral use: US prescribing information. 2018. Accessed 4 Nov 2019.
  9. 9.
    Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–20.CrossRefGoogle Scholar
  10. 10.
    Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations